Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

UBS
Fish and Richardson
AstraZeneca
Dow
Medtronic
Queensland Health
Merck
Cantor Fitzgerald
Mallinckrodt
Daiichi Sankyo

Generated: January 21, 2018

DrugPatentWatch Database Preview

Tasimelteon - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for tasimelteon and what is the scope of tasimelteon freedom to operate?

Tasimelteon
is the generic ingredient in one branded drug marketed by Vanda Pharms Inc and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Tasimelteon has eighty-nine patent family members in thirty countries.

There are three drug master file entries for tasimelteon. One supplier is listed for this compound.
Summary for tasimelteon
International Patents:89
US Patents:6
Tradenames:1
Applicants:1
NDAs:1
Drug Master File Entries: 3
Suppliers / Packagers: 1
Bulk Api Vendors: 26
Clinical Trials: 15
Patent Applications: 41
Drug Prices:see low prices
DailyMed Link:tasimelteon at DailyMed
Pharmacology for tasimelteon

US Patents and Regulatory Information for tasimelteon

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Vanda Pharms Inc HETLIOZ tasimelteon CAPSULE;ORAL 205677-001 Jan 31, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Vanda Pharms Inc HETLIOZ tasimelteon CAPSULE;ORAL 205677-001 Jan 31, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Vanda Pharms Inc HETLIOZ tasimelteon CAPSULE;ORAL 205677-001 Jan 31, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Vanda Pharms Inc HETLIOZ tasimelteon CAPSULE;ORAL 205677-001 Jan 31, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Vanda Pharms Inc HETLIOZ tasimelteon CAPSULE;ORAL 205677-001 Jan 31, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Vanda Pharms Inc HETLIOZ tasimelteon CAPSULE;ORAL 205677-001 Jan 31, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Vanda Pharms Inc HETLIOZ tasimelteon CAPSULE;ORAL 205677-001 Jan 31, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Vanda Pharms Inc HETLIOZ tasimelteon CAPSULE;ORAL 205677-001 Jan 31, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for tasimelteon

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
RE46604 Treatment of circadian rhythm disorders ➤ Subscribe
5,981,571 Benzodioxa alkylene ethers as melatonergic agents ➤ Subscribe
6,060,506 Benzopyran derivatives as melatonergic agents ➤ Subscribe
2,017,087,122 ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for tasimelteon

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Accenture
Healthtrust
Federal Trade Commission
McKinsey
Dow
Cipla
Mallinckrodt
Fuji
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot